HEALEY ALS Platform Trial - Regimen D Pridopidine

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

HEALEY ALS Platform Trial - Regimen D Pridopidine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04615923
• Other study ID #: 2019P003518D
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: December 18, 2020
• Est. completion date: July 14, 2022

Study information

• Verified date: August 2023
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.

Description:

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.

Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.

If a participant is randomized to Regimen D Pridopidine, the participant will complete a screening visit to assess additional Regimen D eligibility criteria. Once Regimen D eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active pridopidine or matching placebo.

Regimen D will enroll by invitation, as participants may not choose to enroll in Regimen D. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen D.

For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 163
• Est. completion date: July 14, 2022
• Est. primary completion date: July 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

Exclusion Criteria:

• The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

1. Participants with a confirmed prolonged Fridericia-corrected QT (QTcF) interval (defined as a QTcF interval of >450 ms for men and >470 ms for women).

2. Participants with clinically significant heart disease, clinically significant history of arrhythmia, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia, or presence of left bundle branch block.

3. Participants with known history of long QT syndrome or a first degree relative with this condition.

4. Participants using prohibited medications within the 4 weeks prior to the Regimen Specific Screening Visit, as detailed in section 5.9.

5. Participants using the following medications at the time of the Regimen Specific Screening Visit:

1. Nuedexta - at a dosage higher than 20 mg dextromethorphan + 10 mg quinidine BID

2. Citalopram - at a dosage higher than 20 mg/day

3. Escitalopram - at a dosage higher than 10 mg/day

6. Participants with a known allergy to any ingredient of the study intervention (pridopidine, silicified microcrystalline cellulose, and magnesium stearate).

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease

Intervention

Drug:
• Pridopidine
Administration: Oral Dose: 45mg twice daily
• Matching Placebo
Administration: Oral Dose: one capsule twice daily

Locations

Country	Name	City	State
United States	Healey Center for ALS at Mass General	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Merit E. Cudkowicz, MD	Prilenia Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Progression as Assessed by the ALSFRS-R Total Score	Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.	Baseline to 24 Weeks
Primary	Mortality Event Rate	Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.	Baseline to 24 Weeks
Secondary	Change in Bulbar Function in Participants With Bulbar Dysfunction at Baseline	Change in bulbar function over time in participants with bulbar dysfunction at baseline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.; Participants were classified as having bulbar dysfunction at baseline if their score on the ALSFRS-R bulbar domain (Q1-Q3) score was less than 12.	Baseline to 24 Weeks
Secondary	Bulbar Function in All Randomized Participants	Change in bulbar function over time in all randomized participants as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.	Baseline to 24 Weeks
Secondary	Respiratory Function	Change in respiratory function over time as measured by Slow Vital Capacity (SVC).	Baseline to 24 Weeks
Secondary	Bulbar Function in Participants With Rapid Pre-baseline Progression	Change in bulbar function over time in participants with rapid pre-baseline progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.; Participants were classified with rapid pre-baseline progression if their change in ALSFRS-R total score between Master Protocol Screening and Regimen Baseline was greater than or equal or 0.75 points per month.	Baseline to 24 Weeks
Secondary	Time to Bulbar Decline	Time to first decline of 1-point or greater post baseline in the ALSFRS-R bulbar domain score among all participants.; Analysis performed using interval-censored survival analysis. Results presented as median interval (upper & lower bounded) time to event.	Baseline to 24 Weeks
Secondary	Muscle Strength	Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).	Baseline to 24 Weeks
Secondary	Number of Participants That Experienced Death or Death Equivalent	The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.	Baseline to 24 Weeks